Mind Medicine announces a reverse share split of its common shares at a 1-15 ratio. Exchange symbols will remain the same but new CUSIP numbers will be assigned by the appropriate regulators.
Exploring the companies and themes that make up this emerging and exciting new sector
COMPASS Pathways plc announces second quarter 2022 financial results and business highlights
Compass Pathways reports its Q2 2022 results. Preparing for its Phase 3 clinical trial for TRD. Net loss of $21.0 million. Cash (and equivalents) of $207.2 million.
COMPASS Pathways launches phase II clinical trial of psilocybin therapy in anorexia nervosa
Compass Pathways announces the launch of a Phase II clinical trial using psilocybin-based COMP360 as a treatment for anorexia nervosa.
COMPASS Pathways appoints Kabir Nath as Chief Executive Officer
Compass Pathways announces that Kabir Nath will replace George Goldsmith as CEO effective August 1, 2022.
BetterLife Secures Additional Mitacs Funding in Collaboration with Carleton University Research Team for BETR-001 Preclinical Depression Studies
Better Life Pharma announces additional funding to study BETR-001 as a treatment for depression, via the Mitacs Accelerate program.
Red Light Holland and Superstar Wiz Khalifa to Launch Naturally Occurring Psilocybin and Mushrooms Wellness Brand: Mistercap
Red Light Holland announces a partnership with platinum-selling rapper, Wiz Khalifa, to launch Red Light Holland's MISTERCAP brand of psilocybin-based products.
Cybin Receives FDA IND Clearance for its Phase 1/2a Clinical Trial Evaluating CYB003 for the Potential Treatment of Major Depressive Disorder
Cybin announces receipt of its "may proceed letter" from the U.S. Food and Drug Administration (FDA) regarding its Phase 1/2a clinical trial of CYB003 for major depressive disorder (MDD).
Cybin Inc. Reports Fiscal Year 2022 Financial Results and Recent Business Highlights
Cybin Inc reports its fiscal year 2022 financial results, including progress on several pipeline initiatives, with a cash balance of CAD$53.6 million as of March 31, 2022.
Numinus Pilots Mental Health Program for Corporate Clients in Utah
Numinus announces a pilot program to encourage employers to offer ketamine-assisted psychotherapy to employees as a health benefit.
BetterLife To Present BETR-001 Preclinical Data at the Upcoming Federation of European Neuroscience Societies (FENS) Forum
Better Life Pharma will be presenting an abstract on its lead compound, BETR-001, to the European Neuroscience Societies (FENS) Forum in July.
Optimi Health Requests Approval To Manufacture MDMA, Other Synthetic Psychedelics
Optimi files an application with Health Canada to synthesize, process and produce pharmaceutical grade 3,4-Methylenedioxymethamphetamine ("MDMA").
Numinus completes acquisition of Novamind and announces executive appointments
Numinus Wellness announces the completion of its acquisition of Novamind Inc, with Novamind shareholders receiving 0.84 shares of Numinus per Novamind share.